奥西默替尼
医学
后天抵抗
胶质母细胞瘤
肺癌
酪氨酸激酶
酪氨酸激酶抑制剂
癌症研究
癌症
生物
肿瘤科
内科学
埃罗替尼
表皮生长因子受体
受体
出处
期刊：Cancer Discovery
[American Association for Cancer Research]
日期：2021-10-26
卷期号：11 (12): 2952-2953
被引量：4
标识
DOI：10.1158/2159-8290.cd-nb2021-0395
摘要
According to a preclinical report, the investigational tyrosine kinase inhibitor BDTX-1535 may mitigate resistance to osimertinib, the standard of care for EGFR-mutant non-small cell lung cancer. It could also potentially treat central nervous system metastases, having shown preclinical efficacy in glioblastoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI
Grayball
浦肯野
nozero
pcr163
andrele
YifanWang
brian0326
从容芮
醉书生
MchemG
Oracle
CAOHOU
JPH1990
VDC
NJD
复杂书竹
zinnn
子凡
shinysparrow
Randall
皖公网安备34019202002308
